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Summary
i
Studies measuring the fibrin degradation product D-Dimer (DD) 
using enzyme-linked immunosorbent assays (ELISA) in patients with 
venographically proven deep venous thrombosis (DVT) suggest that it 
is possible to exclude DVT when DD level is below a certain cut-off 
level However, ELISA methods are time-consuming and not available 
in all laboratories. Different rapid latex-agglutination assays have been 
investigated, but their sensitivity is considerably lower.
In the present study we compared the value of four novel latex DD 
tests (Tinaquant®, Minutex®, Ortho® and SimpliRed®) and one rapid 
ELISA (VIDAS®) to a classical ELISA DD assay (Organon Mab Y 18®) 
in 132 patients suspected of DVT.
The VIDAS®, a new quantitative automated ELISA, had a sensitiv­
ity of 100% and a negative predictive value of 100% for both proximal 
and distal DVT at a cut-off level of 500 ng/ml. The Tinaquant® assay, a 
new quantitative latex method, had a sensitivity of 99% and a negative 
predictive value of 93% for both proximal and distal DVT at a cut-off 
level of 500 ng/ml. For proximal DVT only, both assays had a sensitiv-
»
ity and negative predictive value of 100%. VIDAS® and Tinaquant® 
correlated well with ELISA (correlation of r = 0.96 and r = 0.98 
respectively). Sensitivities of the semi-quantitative latex assays 
Minutex®, Ortho® and SimpliRed® were considerably lower (77%, 
51% and 61% respectively).
These results suggest that VIDAS® and Tinaquant® may be used 
instead of ELISA DD in the exclusion of DVT. Tinaquant® can be per­
formed within 20 min and VIDAS® within 35 min. Both assays might 
be used as a routine screening test and should be evaluated in large 
clinical management studies.
Introduction
In order to prevent the morbidity and mortality associated with 
untreated deep venous thrombosis (DVT) a reliable diagnosis and 
therapy is required. The clinical diagnosis of DVT is unsatisfactory. 
Over 50% of patients with symptoms suggesting DVT do not have 
thrombosis (1-3). The definitive test for the diagnosis of DVT is still 
classical ascending venography. Because this technique is invasive 
several noil-invasive tests have been developed over the past three
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decades (4, 5). None of these has been able to achieve the absolute 
degree of anatomical definition that is possible with contrast venogra­
phy, but some of these tests have a diagnostic threshold that permits 
safe clinical management. Serial use of ultrasonography has recently 
been shown to be a safe method of managing outpatients who are 
suspected of having lower limb DVT (6). However, a simple and 
reliable blood test that could exclude DVT would have practical and 
economic advantages.
Increased levels of plasma D-Dimer (DD) -  a cross-linked fibrin 
degradation product reflecting fibrin formation and subsequent dissolu­
tion -  measured by enzyme-linked immunosorbent assay (ELISA), 
have been reported in patients with proven DVT by venography (7-10). 
One of the major problems of blood tests for DVT is the lack of 
specificity of the markers. Elevated levels of DD are also found in a 
wide variety of other clinical conditions (e. g. myocardial infarction, 
inflammation, malignancy and liver disease) (11). As a consequence 
*
studies measuring DD in patients with venographically proven DVT 
suggest that it should only be possible to exclude this condition.
A series of different assays have been evaluated for the presence or 
absence of DVT. ELISA assays have been proven to be sensitive 
enough, but this technique is rather time-consuming (it takes about
2 h) and not suited for routine measurements and thus has little cLinical 
utility as a routine screening test (7,12). DD latex agglutination assays 
are performed more rapidly, but their sensitivity is considerably 
lower (9, 10,13-19). Recently DD latex assays have regained interest 
as an emergency diagnostic, because newly available assays display 
higher sensitivity . In the present study the value of five novel, rapid DD 
assays in the exclusion of DVT in outpatients with suspected DVT was 
assessed and compared to ELISA.
Patients and Methods
Patients
In two clinical centers (University Hospital Nijmegen and Canisius 
Wiihelmina Hospital) patients referred to the outpatients department or 
emergency unit because of clinically suspected DVT were enrolled in the study 
after giving informed consent. Only ambulant outpatients were included. No 
other exclusion criteria were applied. At the time of inclusion age, gender, 
duration of symptoms and risk factors (immobilization, previous DVT, surgery, 
malignancy, pregnancy, oral contraceptives) were recorded.
Vascular Testing
After blood was drawn patients were submitted to compression ultrasound 
(C-US) of the affected extremity. The deep venous system from the popliteal to 
the iliac vein was examined (4, 20, 21). Lack of full compressibility was the 
sole criteria for DVT. In case of a positive result, patients were administered for
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false positive fraction  (%)
Fig. ] ROC curve analysis of the accuracy of Tinaquant® plasma concentra­
tions for DVT detected by compression ultrasound or venography, D-Dimer 
values (ng/ml) corresponding to sensitivities of 49%, 60%, 75%, 89% and 99% 
are shown
Table 1 Sensitivity, specificity, positive predictive value and negative
predictive value of the different DD-assays
Assay sens (%) 
Cl
spec (%) 
Cl
NPV (%) 
Cl
PPV {%) 
Cl
Duration of the 
test (minutes)
ELISA 98 36 88 77 120
(500 ng/ml) 95-100 21-51 80-96 73-81
VIDAS 100 19 100 72 35
(500 ng/ml) 97-100 7-30 69-100 64-80
Tinaquant 99 33 93 76 20
(500 ng/ml) 97-100 18-48 80-100 68-84
SimpliRed 61 90 52 93 5
51-71 81-99 29-75 86-100
Minutex 77 64 56 82 5
68-86 49-79 27-85 74-90
-
Ortho 51 47 47 94 5
29-73 32-62 25-69 87-100
sens = sensitivity
spec — specificity
NPV = negative predictive value
PPV = positive predicitive value
Cl =  95% confidence interval
standard anticoagulant therapy. Whenever the C-US was inconclusive, that 
means in case the deep veins could not be adequately visualized, venography 
was performed and regarded as the definitive test. Also each time distal DVT 
was suspected venography was performed. If negative C-US results were 
obtained, C-US was repeated between 3 and 7 days after the initial testing if 
clinical symptoms of DVT persisted.
Laboratoiy Testing
At the time of initial presentation from all patients 4.5 ml of blood was 
drawn into a vacutainer tube containing 0.5 ml 3.8% sodium citrate. Platelet 
poor plasma was prepared by centrifugation at 4000 X g for 10 min. Plasma
Table 2 Sensitivity and negative predictive values of the different assays for 
proximal DVT
Assay sens overall 
(* )
sens prox 
(%)
NPV overall 
(%)
NPV prox 
(%)
ELISA (500 ng/ml) 98 99 88 94
VIDAS (500 ng/ml) 100 100 100 100
Tinaquant (500 ng/ml) 99 100 93 100
Simplired 61 63 52 56
Minutex 77 78 56 60
Ortho 51 54 47 51
sens — sensitivity 
NPV = negative predictive value 
overall = proximal + distal 
prox — proximal
was snap-frozen in aliquots and stored at -70° C until assayed. DD assays were 
performed using commercially available kits. The results of the tests were not 
made known to the person performing the vascular testing and the results of the 
vascular testing were not known to the laboratory technician. Because some of 
the assays are subject to inter-observer variability each assay was performed at 
the same time by the same laboratory technician. The following DD-assays 
were performed: (1) ELISA: Mah Y 18® (Organon Teknika, Belgium) and (2) 
VIDAS® (Biomérieux, France), a quantitative ELISA method automated on 
VIDAS immunoanalyzer. Latex: (3) Ortho® Dimertest (Ortho diagnostic 
systems Inc, Belgium), (4) Minutex® (Biopool, Sweden), (5) SimpliRed® 
(Agen diagnostics limited, Australia) and (6) Tinaquant® (Boehringer Mann­
heim, Germany). Ortho® and Minutex® D-Dimer are semi-quantitative assays; 
agglutination taking place in undiluted plasma was regarded as a positive test. 
SimpliRed® is an autologous red cell agglutination assay. This assay can be per­
formed immediately in whole blood. For practical reasons we centrifugated the 
blood and stored the plasma until assayed. At the time of the assay erythrocytes 
were added (“add-back” procedure). Tinaquant® is a new quantitative latex 
assay. It was performed on a Hitachi 911 clinical chemistry analyzer. It has 
been standardized before against the ELISA test Asserachrom® D-Dimer and 
the correlation between the two assays was 0.998 (22).
Analysis
The presence or absence of DVT was determined on the basis of the 
vascular testing. The sensitivity, specificity and positive and negative 
predictive values with 95% confidence limits (Cl) of each assay were calculat­
ed according to the presence of DVT on ultrasonography or venography using 
two by two tables. For ELISA, VIDAS® and Tinaquant® Receiver Operator 
Characteristics (ROC) curves were constructed by plotting the sensitivity (true 
positive fraction) versus 1-specificity (false positive fraction) (23). Cut-off 
values were chosen based on optimal sensitivity and negative predictive value. 
Correlation was calculated according to Spearman.
Results
«
During the study period (March-December 1995) 132 patients 
(83 females and 49 males) were enrolled. The mean age was 59 years 
(range 22 to 89 years). In 78 patients proximal DVT was detected by 
C-US. In 26 patients venography was performed; in 11 patients distal 
DVT was detected and in 15 patients venography was negative. In 28 
patients C-US was negative. Only one patient with an initially negative
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Fig. 2 Correlation between the 
ELISA and VIDAS® (r = 0.96) and 
Tinaquant® assay (r = 0.98)
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Fig. 3 Values of the VIDAS® and Tinaquant® assays in three different groups 
of patients; no DVT, distal DVT and proximal DVT. All patients exceeding 
DD 10,000 ng/ml got the value 10,000 in the figure. DVT = deep venous 
thrombosis
i
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C-US developed persisting symptoms and was found to have vein 
incompressibility at follow-up. In summary proximal DVT was detect­
ed in 59% and distal DVT in 8% (overall prevalence 67%). Risk factors 
for DVT were found in 66 patients (73%) in the group with DVT (14 
immobilization, 20 malignancy, 13 previous DVT, 2 previous surgery, 
6 recent pregnancy, 11 oral anticonceptives) and in 21 patients (50%) in 
the group without DVT (2 immobilization, 3 malignancy, 5 previous 
DVT, 7 recent surgery, 4 oral anticonceptives).
The ROC curve of the accuracy of Tinaquant® for all detected D VT 
is shown in Fig* 1. The ROC curve for ELISA and VIDAS® was deter­
mined in the same way. For both assays sensitivity and specificity were 
optimal at a cut-off level of 500 ng/ml. Table 1 shows the overall 
sensitivity, specificity, positive and negative predictive values of the 
different assays. At a cut-off level of 500 ng/ml overall sensitivities for 
ELISA, VIDAS® and Tinaquant® were 98%, 100% and 99% respec­
tively. Negative predictive values were 88%, 100% and 93% respec­
tively* The sensitivities of the three other latex tests were considerably 
lower (respectively 61%, 77% and 51% for Simplired®, Minutex® and 
Ortho®). Table 2 shows the sensitivity and negative predictive value for 
proximal DVT only; sensitivity and negative predictive value for 
VIDAS® and Tinaquant® were both 100%. Fig. 2 shows that there was 
a good correlation between ELISA and VIDAS® (r = 0.96) and between 
ELISA and Tinaquant® (r = 0.98), Fig. 3 shows the results of the 
VIDAS® and Tinaquant® tests for three categories of patients: (1) 
absence of DVT, presence of (2) distal and (3) proximal DVT, Values 
exceeding 10,000 ng/ml were exclusively found in patients with a 
proven DVT. Fig. 3 shows that the results of both assays are very 
similar and that according to both assays in all patients with DVT 
(except for one patient with distal DVT) the DD exceeded 500 ng/ml.
Discussion
The rationale for performing this study was to see if it was feasible 
to use a rapid screening test to exclude the presence of DVT in out­
patients. We excluded inpatients because DD is elevated in many other
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pathological/comorbid conditions (e. g. malignancy, infection, myocar­
dial infarction, liver disease) (11).
Most hospitals are using non-invasive tests to evaluate diagnosis of 
DVT. C-US has proven to be the most reliable diagnostic test (6). 
Serial testing is necessary to detect ascending distal DVT. We 
compared the diagnostic efficacy of five rapid DD assays with classical 
ELISA in clinically suspected DVT. The diagnosis of DVT was made 
by C-US. Venography, considered as “gold standard” was not per­
formed routinely. However, if C-US was inconclusive or if distal DVT 
was suspected, venography was performed. If clinical symptoms 
persisted serial C-US was performed. In only one patient vein incom­
pressibility developed at follow-up.
Because many patients with symptoms suggestive of DVT appear 
not to have DVT by objective testing (1,2), a simple screening test to 
rule out DVT reliably, would avoid unnecessary further diagnostic 
procedures. Ideally such a test must have a high sensitivity in order to 
rule out the diagnosis DVT correctly as these patients would be 
undertreated.
Classical ELISA assays have proven to be sensitive (7, 12). The 
disadvantage of ELISA tests is that they are time-consuming and not 
suitable for routine measurement. In view of the fact that ELISA tests 
last at least 120 min and that latex agglutination methods are extremely 
simple and rapid to perform (5-20 min), the availability of a reliable 
latex test is most interesting. The studies reported using latex tests 
showed discordant results (10, 12, 14). Sensitivities of most of the 
currently available latex assays are not sufficiently high, except for the
recently developed SimpliRed® assay (24); Wells et al. demonstrated a
i
sensitivity of 93% and a negative predictive value of 98% for this assay.
More rapid ELISA and more sensitive latex DD assays have been 
developed recently. We investigated the accuracy of a rapid ELISA 
(VIDAS®) and 4 latex assays (Tinaquant®, Minutex®, Ortho® and 
SimpliRed®). The results of VIDAS® and Tinaquant® were equal to 
those of previous reports about ELISA. We also found a good correla­
tion with the classical ELISA (r = 0.96 and r = 0.98 for VIDAS® and 
Tinaquant® respectively). For VIDAS® these results are comparable to 
former studies (25, 26). Both' assays have 100% sensitivity 
(Cl 97-100%) and 100% negative predictive value (Cl 80-100%) for 
proximal DVT. The measurement of plasma DD in symptomatic pa­
tients with clinically suspected DVT allows exclusion of proximal 
DVT when negative (<500 ng/ml); the negative predictive value of the 
test being 100% (Cl 80-100%). The specificity of VIDAS® and 
Tinaquant® was relatively low (respectively 19% and 33%). As it 
means that according Tinaquant® one third of the patients without DVT 
could be sent home without further investigations it may be concluded 
that it might be a useful test as first screening in outpatients. The 
specificity of VIDAS® is lower than previously reported (25, 26). In 
this study only 8 out of 42 patients without DVT could have been sent 
home without further investigations. Another disadvantage of VIDAS® 
is that this ELISA can only be performed on a dedicated analyzer, while 
Tinaquant® can be performed on routine clinical chemistry analyzers 
such as the Hitachi, which is used in this study.
The remaining three latex tests had a lower sensitivity and negative 
predictive value when compared to standard non-invasive tests. These 
cannot be regarded as adequate. This lack of sensitivity has been 
observed in other studies. The results of the SimpliRed® assay were 
different from the sensitivity and negative predictive value reported by 
Wells et al. (24). However, they performed the DD assay immediately 
in whole blood, whereas for practical reasons we centrifugated the 
blood and stored the plasma until assayed. At the time of the assay 
erythrocytes were added (“add-back“ procedure). This might be the
reason of the different results. Both alternatives of performing the 
Simplired® assay should be compared to assure this explanation.
The prevalence of DVT in our group of patients was relatively high 
compared to other studies. In these studies prevalence varies between
30 and 50%. A reason for this might be the strict referral pattern of the 
general practitioners to our hospital reflected in the relatively high 
number of patients with risk factors for DVT, Another reason might be 
that during the night hours we missed some samples of patients with a 
negative C-US.
In summary the VIDAS® and Tinaquant® assays used in this study 
appeared to be suitable in the exclusion of DVT. The problem of 
the other semi-quantitative latex tests was insufficient sensitivity. 
Although the tests have a high negative predictive value (100%, 
Cl 80-100%), the safety of withholding anticoagulant therapy in 
patients with clinically suspected DVT and negative DD needs 
confirmation in a prospective trial of a large number of consecutive out­
patients. Based on these results management studies should be per­
formed to examine the safety and cost-effects of this approach.
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